Selective inhibitor of TGF-β
type-I receptor (TGF-β
RI, TGFR-I, Tβ
R-I, ALK-5) (IC50
values are 59, 400 and 1400 nM for TGR-β
RII and MLK-7K respectively). Inhibits TGF-β
-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC50
values are 47 and 89 nM respectively). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-μ type I receptor kinase domain.
Sawyer et al.
Dihydropyrrolopyrazole transforming growth factor-β type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-β type II receptor kinase and mixed lineage kinase 7.
Li et al.
Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-β.
Shiou et al.
The citations listed below are publications that use Tocris products. Selected citations for LY 364947 include:
Showing Results 1 - 8 of 8